endorphins, and cannabinoids. 13 We know that inhibiting some of these pathways is effective in alleviating chemotherapy-related vomiting, although these same methods have not done a good job of alleviating chemotherapy-related nausea. This suggests that different pathways may play a role in the manifestation of nausea.
The most widely studied compound related to the development of CINV is serotonin, also known as 5-HT. 5-HT is produced by enterochromaffin cells, a unique cell type dispersed throughout the enteric epithelium. These cells constitutively express 5-HT and 5-HT is expressed more abundantly upon exposure to a chemotherapeutic agent. At elevated levels, 5-HT is released from the basal surface into the lamina propria. There, secreted 5-HT binds to cognate 5-HT 3 receptors located on vagus nerve terminals, thus acting as a neurotransmitter transducing a signal to the hindbrain. In turn, the translated signal triggers a motor response of nausea and vomiting, carried by efferenting vagal nerves. receptor function. 9 Moreover, palonosetron has a half-life of 40 hours, which may allow more effective prevention of delayed nausea and vomiting than can be achieved with the other 5-HT 3 antagonoists. 16 Additionally, palonosetron may act to influence the neurokinin-1 receptor (NK-1) pathway as there is downstream cross-talk between 5-HT 3 and NK-1 receptor pathways.
10
Since 5-HT synthesis is increased significantly after chemotherapy, another method of potential therapeutic benefit would decrease 5-HT synthesis in the gut. Since 5-HT synthesis is dependent on tryptophan hydroxylase (TPH), this enzyme may represent a viable and more broadly acting target. Pre-clinical studies have been conducted using a TPH inhibitor to selectively inhibit 5-HT in the gut using a ferret model of chemotherapy-induced emesis.
17
Substance P is another strong regulator of the emetic response; it binds to the NK-1 receptor. Both substance P compound and NK-1 receptor are found within the CNS and also within the gut. Compared with 5-HT/5-HT 3 receptor interaction, less is known about how and where substance P and NK-1 act in promoting emetic potential, although peripheral and central components may be involved. Pre-clinical studies suggest that antagonizing NK-1 receptor action in the CNS is key to preventing nausea and vomiting, as agents not capable of crossing the blood-brain barrier do not protect against emesis.
18
Clinically, administration of aprepitant, the first drug devised to antagonize the NK-1 receptor, has proved effective in preventing NV when combined with 5-HT 3 receptor antagonists.
19-21
Other pathways controlling the emetic reflex exist, but far less is known about their regulation of the emetic response, especially in CINV. For example, dopamine release and cognate dopamine receptor-2 signaling may play a role, as dopamine antagonists have been shown to be effective in treating nausea and vomiting. Additionally, while participation of the CNS is clearly a major contributor to the emetic process, it is also possible the enteric nervous system itself may be able to control nausea and vomiting effects without CNS interplay.
Understanding of the role of mediators in the pathologic development of CINV will advance the development of a broader range of more effective anti-emetic treatments for CINV. Further research on the physiologic mechanisms involved in the development of nausea and vomiting is needed to develop therapies to fully eradicate anticipatory, acute, and delayed CINV.
Pathopsychology of Nausea and EmesisThe Role of Conditioning and Cognition
ANV occurs before chemotherapy infusion. ANV is believed to be a conditioned response, such that ANV will occur only after a patient has experienced nausea and/or vomiting in response to chemotherapy treatment. 22 However, there are reports of ANV developing without an individual previously experiencing post-treatment nausea (e.g. in children). 23 The general understanding of ANV as a conditioned response is that contextual factors, such as the sights, sounds, and smells of the clinic, become conditioned stimuli paired to the unconditioned stimulus (the chemotherapy agent) that produces the unconditioned response (nausea and vomiting). Therefore, the conditioned stimuli come to elicit the conditioned response: nausea and vomiting prior to chemotherapy (ANV). There is support for ANV as a conditioned response through correlational studies, 24-26 as well as through laboratory models in humans and rats. 25 The 2012 National Comprehensive Cancer Network (NCCN) Guidelines recommend that ANV be prevented through optimal anti-emetic therapy during every cycle of chemotherapy. 22 Despite decreases in the frequency of post-treatment emesis over time, decreases in ANV were not observed in a large community study. 28 Therefore, ANV continues to be a problem for patients despite advances and aggressive treatment with anti-emetics. 28 The conditioning paradigm does not fully account for the development of ANV, and cognitive factors have been identified as contributors to ANV, including anxiety and response expectations. 5, 6, 11, 26, [32] [33] [34] [35] [36] Anxiety is believed to contribute to ANV, at least in part, through negative expectations. 33, [37] [38] [39] The relationships between anxiety and negative expectations are reciprocally interactive. For example, increased anxiety produces negative expectations and negative expectations increase anxiety.
Evidence suggests that a patient's expectations of experiencing nausea strongly predict the actual occurrence of ANV. 34, 40 It is most likely that a combination of classic conditioning and expectancy theories more fully explain the psychopathology of ANV because conditioning effects are mediated by patient expectations and conditioning effects moderate patient expectations. [41] [42] [43] A patient's expectations of nausea are also a strong predictor of post-treatment nausea even when controlling for other known contributors. [44] [45] [46] [47] [48] [49] [50] Individual variation in patient expectations may also explain why the frequency and severity of CINV are different for different patients on the same chemotherapy regimens. These between-patient differences cannot be fully accounted for by the properties of the chemotherapy agents or patient demographic characteristics. 30, 50, 51 Patient and treatment factors associated with CINV include female gender, younger age, lower alcohol intake history, history of motion sickness, history of emesis during pregnancy, history of CINV, and pre-treatment expectations of nausea. 52 Family conflict has been found to be related to post-treatment nausea and ANV for younger adult and female patients. 53 Additional cognitive and behavioral interventions that focus on changing expectations are needed as adjuncts to standard pharmaceutical anti-emetic therapies to help fully control anticipatory, acute, and delayed CINV. Roscoe and colleagues found that using a cognitive manipulation technique to increase beliefs that acupressure bands could prevent CINV resulted in significantly reduced CINV among patients with high initial expectations of experiencing CINV. 49 These findings enhance our understanding of factors that contribute to CINV.
The combined use of techniques such as systematic desensitization, overshadowing, and expectation manipulation with pharmaceutical interventions may lead to more effective management of CINV. More research is needed investigating the psychopathology of CINV to effectively manage the full spectrum of anticipatory, acute, and delayed CINV.
Integrative Medicine Interventions
Integrative medicine approaches, consisting of both complementary and alternative medicine interventions, are commonly used by cancer patients to reduce the toxic adverse effects of chemotherapy treatment. Patients typically use these types of intervention along side their traditional allopathic (e.g. pharmaceutical) interventions.
Integrative modalities are used by the majority of patients with cancer and are most commonly used by patients with advanced-stage disease. 54, 55 These types of treatment usually do not require a prescription from a physician, can be accessed in the community, and are gaining increasing scientific evidence to support their use.
Herbal Supplements
Ginger is the most abundantly used supplement for the prevention and/or reduction of CINV. Since the 16th century, the dried aromatic rhizome (underground stem) of ginger (Zingiber officinale) has been used by practitioners of both Indian (Ayurvedic) and traditional Chinese medicine to treat gastrointestinal upsets such as nausea and excessive flatulence. 56 Ginger has been thoroughly studied and found to be useful for nausea and vomiting associated with motion sickness, surgery, and pregnancy. [57] [58] [59] [60] [61] [62] [63] [64] [65] Three published studies favored use of Chinese medicinal herbs for the relief of CINV. Shenqi fuzheng injections (consisting of two herbs), 71 Aidi injections (consisting of four herbs), 72 and Aifukang (consisting of 11 herbs) 73 reduced CINV in a sample of breast cancer patients.
55
Acupuncture and Acupressure
Acupuncture is another form of traditional Chinese medicine that has been used for centuries to treat nausea and vomiting. Over the past 20 years, clinical evidence has supported the use of acupuncture for CINV. 74 Acupuncture is a 4,000-year-old therapeutic technique that involves inserting and manipulating needles with and without electrical stimulation and providing pressure or electrical stimulation at specific points in the body. 74 Research suggests that acupuncture works primarily on the nervous system through stimulating brain activation or 
Biopsychobehavioral
Biopsychobehavioral interventions such as progressive muscle relaxation, guided imagery, hypnosis, and exercise are also efficacious therapies for the treatment of anticipantory, acute, and delayed CINV.
Biopsychobehavioral interventions are especially appropriate and most beneficial if implemented in a preventive manner and started before the first chemotherapy treatment cycle and, most importantly, before the first onset of symptoms of CINV. 80, 81 Progressive muscle relaxation (PMR) involves the tension and relaxation of muscle groups in sequence to relax physically and mentally. 81 PMR alone reduces the severity of nausea associated with chemotherapy. 82 PMR combined with a 20-minute massage during chemotherapy infusions reduces the severity of nausea. 83 Guided imagery, a technique used to focus a patient's attention on a particular image and associated sensory experiences, reduces the incidence of vomiting in the 24 hours after chemotherapy. 84 Patients who use guided imagery combined with an anti-emetic regimen versus an antiemetic alone have a more positive chemotherapy experience. 85 PMR is often combined with guided imagery to treat CINV with consistent, positive outcomes. PMR combined with guided imagery reduces the incidence of nausea 86, 87 and vomiting 84, 86, 87 in the first four days after chemotherapy and the severity of nausea 83, [87] [88] [89] [90] [91] and vomiting 87, 89 up to five days following chemotherapy.
Cognitive distraction and systematic desensitization have been used to successfully reduce the severity of ANV 92, 93 and CINV. 88, 93 Overshadowing is another technique that has been used to help alleviate ANV. 25, 31 Teaching self-hypnosis, which typically involves using the imagination to suggest feeling good and feeling safe, reduces the incidence of ANV 92, 94 and the severity of CINV 95 in children undergoing chemotherapy.
Hypnosis has also been used successfully with adults to reduce ANV. 96 Several researchers have used exercise interventions to aid in reducing CINV. Aerobic exercise has been shown to help reduce the severity of CINV 97 and yoga has been shown to be beneficial in reducing CINV. Aprepitant is a three-day regimen, with a recommended dosage of 125 mg orally on hour prior to chemotherapy treatment (day one) and 80 mg orally once daily in the morning on days two and three. Fosaprepitent is a prodrug of aprepitant for injection (115 mg over 15 minues) and can be substituted for aprepitant 30 minutes prior to chemotherapy on day one only. In 2003, Hesketh et al. 103 published a randomized, double-blind, parallel-group, placebo-controlled trial of 530 patients receiving cisplatin (a highly emetogenic agent). The aprepitant group response was superior to that of the standard therapy group in acute and delayed phases, as well as overall. 103 Subsequently, a prospective, randomized, double-blind, parallel study of 866 patients receiving moderately emetogenic chemotherapy over multiple cycles demonstrated the efficacy of aprepitant in prevention of nausea and emesis over all four cycles of treatment. 104 This randomized, placebo-controlled trial also evaluated daily aprepitant with dexamethasone for three days versus a single daily dose of palonosetron with dexamethasone for acute and delayed CINV. The study demonstrated no statistical significance between groups, suggesting that one dose of aprepitant with a standard anti-emetic regimen has similar effectiveness to a three-day aprepitant regimen for CINV. 104 The use of aprepitant may also provide an advantage in that patients have to take only one dose of dexamethasone on day one with moderately emetic chemotherapy regimens. 105 Fosaprepitant may offer an option for patients who cannot tolerate oral administration of anti-emetics, particularly during an episode of severe nausea or vomiting. 
